[go: up one dir, main page]

AU2003295086A1 - Single chain antibodies produced in a transgenic mouse - Google Patents

Single chain antibodies produced in a transgenic mouse

Info

Publication number
AU2003295086A1
AU2003295086A1 AU2003295086A AU2003295086A AU2003295086A1 AU 2003295086 A1 AU2003295086 A1 AU 2003295086A1 AU 2003295086 A AU2003295086 A AU 2003295086A AU 2003295086 A AU2003295086 A AU 2003295086A AU 2003295086 A1 AU2003295086 A1 AU 2003295086A1
Authority
AU
Australia
Prior art keywords
single chain
chain antibodies
antibodies produced
transgenic mouse
transgenic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003295086A
Other versions
AU2003295086A8 (en
Inventor
Marianne Bruggemann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Babraham Institute
Original Assignee
Babraham Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Babraham Institute filed Critical Babraham Institute
Publication of AU2003295086A8 publication Critical patent/AU2003295086A8/en
Publication of AU2003295086A1 publication Critical patent/AU2003295086A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Environmental Sciences (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2003295086A 2002-12-03 2003-12-03 Single chain antibodies produced in a transgenic mouse Abandoned AU2003295086A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0228210A GB0228210D0 (en) 2002-12-03 2002-12-03 Single chain antibodies
GB0228210.1 2002-12-03
PCT/GB2003/005274 WO2004049794A2 (en) 2002-12-03 2003-12-03 Single chain antibodies produced in a transgenic mouse

Publications (2)

Publication Number Publication Date
AU2003295086A8 AU2003295086A8 (en) 2004-06-23
AU2003295086A1 true AU2003295086A1 (en) 2004-06-23

Family

ID=9949000

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003295086A Abandoned AU2003295086A1 (en) 2002-12-03 2003-12-03 Single chain antibodies produced in a transgenic mouse

Country Status (3)

Country Link
AU (1) AU2003295086A1 (en)
GB (1) GB0228210D0 (en)
WO (1) WO2004049794A2 (en)

Families Citing this family (127)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0110029D0 (en) 2001-04-24 2001-06-13 Grosveld Frank Transgenic animal
GB0115256D0 (en) 2001-06-21 2001-08-15 Babraham Inst Mouse light chain locus
EP2311874B1 (en) * 2004-07-22 2017-05-31 Erasmus University Medical Center Rotterdam Binding molecules
GB0601511D0 (en) * 2006-01-25 2006-03-08 Univ Erasmus Medical Ct Binding Molecules 2
GB0618345D0 (en) * 2006-09-18 2006-10-25 Univ Erasmus Binding molecules
EP1991580A2 (en) * 2006-01-25 2008-11-19 Erasmus University Medical Center Rotterdam Generation of heavy-chain only antibodies in transgenic animals
EP2514767A1 (en) 2006-12-19 2012-10-24 Ablynx N.V. Amino acid sequences directed against a metalloproteinase from the ADAM family and polypeptides comprising the same for the treatment of ADAM-related diseases and disorders
AU2007336242B2 (en) 2006-12-19 2012-08-30 Ablynx N.V. Amino acid sequences directed against GPCRs and polypeptides comprising the same for the treatment of GPCR-related diseases and disorders
GB0706628D0 (en) * 2007-04-04 2007-05-16 Univ Erasmus Germ-line manipulation 1
DK2152880T3 (en) 2007-06-01 2011-11-28 Omt Inc Compositions and Methods for Inhibition of Endogenous Immunoglobulin Genes and Production of Transgenic Human Idiotype Antibodies
US8975382B2 (en) 2007-11-27 2015-03-10 Ablynx N.V. Amino acid sequences directed against HER2 and polypeptides comprising the same for the treatment of cancers and/or tumors
US9908943B2 (en) 2008-04-03 2018-03-06 Vib Vzw Single domain antibodies capable of modulating BACE activity
DK2281005T3 (en) 2008-04-03 2014-02-24 Vib Vzw Single domain antibodies able to modulate bace1 activity
CN102056945A (en) 2008-04-07 2011-05-11 埃博灵克斯股份有限公司 Amino acid sequences directed against the Notch pathways and uses thereof
MX2010012518A (en) 2008-05-16 2010-12-06 Ablynx Nv AMINO ACID SEQUENCES DIRECTED AGAINST CXCR4 AND OTHER GPCRs AND COMPOUNDS COMPRISING THE SAME.
KR20110020860A (en) 2008-05-23 2011-03-03 알리바 바이오파마수티컬스, 아이엔씨. How to Produce Single LL Domain Antibodies in Transgenic Animals
US9193780B2 (en) 2008-06-05 2015-11-24 Ablynx N.V. Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseases
BRPI0922479A2 (en) * 2008-12-18 2017-07-25 Univ Erasmus Med Ct Rotterdam NON-HUMAN TRANSGENIC ANIMALS THAT EXPRESS HUMANIZED ANTIBODIES AND THEIR USE
WO2010070145A2 (en) 2008-12-19 2010-06-24 Ablynx N.V. Method for generation of immunoglobulin sequences
GB0905023D0 (en) 2009-03-24 2009-05-06 Univ Erasmus Medical Ct Binding molecules
ES2894364T3 (en) 2009-10-22 2022-02-14 Univ Twente VHH for application in tissue repair, organ regeneration, organ replacement, and tissue engineering
CN110079550A (en) 2009-12-10 2019-08-02 瑞泽恩制药公司 Produce the mouse of heavy chain antibody
EP3309176B1 (en) 2009-12-14 2025-10-01 Ablynx N.V. Immunoglobulin single variable domain antibodies against ox40l, constructs and their therapeutic use
WO2011083141A2 (en) 2010-01-08 2011-07-14 Ablynx Nv Method for generation of immunoglobulin sequences by using lipoprotein particles
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
JP5955781B2 (en) 2010-02-08 2016-07-20 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Common light chain mice
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
US9120855B2 (en) 2010-02-10 2015-09-01 Novartis Ag Biologic compounds directed against death receptor 5
US8937164B2 (en) 2010-03-26 2015-01-20 Ablynx N.V. Biological materials related to CXCR7
US9556273B2 (en) 2010-03-29 2017-01-31 Vib Vzw Anti-macrophage mannose receptor single variable domains for targeting and in vivo imaging of tumor-associated macrophages
US9101674B2 (en) 2010-03-29 2015-08-11 Vib Vzw Targeting and in vivo imaging of tumor-associated macrophages
GB201014715D0 (en) 2010-09-06 2010-10-20 Vib Vzw Nanobodies stabilizing functional conformational states of GPCRS
CN103154255B (en) * 2010-08-02 2016-04-06 瑞泽恩制药公司 Mice producing binding proteins containing VL domains
HUE034017T2 (en) 2010-08-26 2018-01-29 Agrosavfe N V Compositions for seed treatment
KR101650995B1 (en) 2010-11-08 2016-08-25 노파르티스 아게 Cxcr2 binding polypeptides
WO2012122512A1 (en) 2011-03-10 2012-09-13 Hco Antibody, Inc. Recombinant production of mixtures of single chain antibodies
US20150158948A9 (en) 2011-03-28 2015-06-11 Francis Descamps Bispecific anti-cxcr7 immunoglobulin single variable domains
UA117218C2 (en) 2011-05-05 2018-07-10 Мерк Патент Гмбх POLYPEPTIDE AGAINST IL-17A, IL-17F AND / OR IL17-A / F
PL2723764T3 (en) 2011-06-21 2018-05-30 Vib Vzw Binding domains directed against gpcr: g protein complexes and uses derived thereof
SI2739740T1 (en) 2011-08-05 2019-12-31 Regeneron Pharmaceuticals, Inc. Humanized universal light chain mice
HUE034321T2 (en) 2011-10-17 2018-02-28 Regeneron Pharma Limited mouse immunoglobulin heavy chain
HRP20190897T1 (en) 2011-12-20 2019-09-20 Regeneron Pharmaceuticals, Inc. Humanized light chain mice
EP2617732A1 (en) 2012-01-19 2013-07-24 Vib Vzw Tools and methods for expression of membrane proteins
US9328174B2 (en) 2012-05-09 2016-05-03 Novartis Ag Chemokine receptor binding polypeptides
EP2855526B1 (en) 2012-05-24 2018-11-07 VIB vzw Anti-macrophage mannose receptor immunoglobulin single variable domains for targeting and in vivo imaging of tumor-associated macrophages
KR102484480B1 (en) 2012-06-12 2023-01-04 리제너론 파마슈티칼스 인코포레이티드 Humanized non-human animals with restricted immunoglobulin heavy chain loci
HUE035315T2 (en) 2013-01-30 2018-05-02 Vib Vzw Novel chimeric polypeptides for screening and drug discovery purposes
JP2016512954A (en) 2013-02-05 2016-05-12 フエー・イー・ベー・フエー・ゼツト・ウエー Binding agents for muscarinic acetylcholine receptors and their use
HRP20181151T1 (en) 2013-02-20 2018-09-21 Regeneron Pharmaceuticals, Inc. Non-human animals with modified immunoglobulin heavy chain sequences
US10993420B2 (en) 2013-03-15 2021-05-04 Erasmus University Medical Center Production of heavy chain only antibodies in transgenic mammals
AU2014229952B2 (en) 2013-03-15 2018-10-04 Vib Vzw Anti-macrophage mannose receptor single variable domains for use in cardiovascular diseases
JP6687525B2 (en) 2014-01-30 2020-04-22 ブイアイビー ブイゼットダブリュＶｉｂ Ｖｚｗ Opioid receptor binding agents and uses thereof
SG11201607015VA (en) 2014-03-21 2016-09-29 Regeneron Pharma V<sb>L</sb> ANTIGEN BINDING PROTEINS EXHIBITING DISTINCT BINDING CHARACTERISTICS
CA3124228C (en) 2014-03-21 2024-05-14 Regeneron Pharmaceuticals, Inc. Non-human animals that make single domain binding proteins
EP3271403A1 (en) 2015-03-19 2018-01-24 Regeneron Pharmaceuticals, Inc. Non-human animals that select for light chain variable regions that bind antigen
IL274151B (en) 2015-05-21 2022-07-01 Harpoon Therapeutics Inc Trispecific binding proteins and methods of use
CN105384825B (en) 2015-08-11 2018-06-01 南京传奇生物科技有限公司 A kind of bispecific chimeric antigen receptor and its application based on single domain antibody
WO2017134302A2 (en) 2016-02-05 2017-08-10 Orionis Biosciences Nv Targeted therapeutic agents and uses thereof
EP3426278B1 (en) 2016-03-07 2024-01-03 Vib Vzw Cd20 binding single domain antibodies
CA3017813C (en) 2016-03-17 2021-12-07 Oslo Universitetssykehus Hf Fusion proteins targeting tumour associated macrophages for treating cancer
US11753463B2 (en) 2016-05-13 2023-09-12 Orionis Biosciences BV Therapeutic targeting of non-cellular structures
BR112018073761A2 (en) 2016-05-20 2019-02-26 Harpoon Therapeutics, Inc. single chain variable fragment cd3 binding proteins
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
CN119060177A (en) 2016-05-20 2024-12-03 哈普恩治疗公司 Single domain serum albumin binding protein
WO2018014260A1 (en) 2016-07-20 2018-01-25 Nanjing Legend Biotech Co., Ltd. Multispecific antigen binding proteins and methods of use thereof
WO2018068201A1 (en) 2016-10-11 2018-04-19 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against ctla-4
MX2019006043A (en) 2016-11-23 2019-09-26 Harpoon Therapeutics Inc Prostate specific membrane antigen binding protein.
BR112019010602A2 (en) 2016-11-23 2019-12-17 Harpoon Therapeutics Inc trispecific psma proteins and methods of use
CN110662421B (en) 2017-01-19 2023-03-24 欧莫诺艾比公司 Human antibodies from transgenic rodents having multiple heavy chain immunoglobulin loci
CN110546160A (en) 2017-02-06 2019-12-06 奥里尼斯生物科学公司 Targeted chimeric proteins and their uses
WO2018160754A2 (en) 2017-02-28 2018-09-07 Harpoon Therapeutics, Inc. Inducible monovalent antigen binding protein
CA3063362A1 (en) 2017-05-12 2018-11-15 Harpoon Therapeutics, Inc. Msln targeting trispecific proteins and methods of use
JP7090347B2 (en) 2017-05-12 2022-06-24 ハープーン セラピューティクス，インク． Mesothelin-binding protein
WO2018222587A1 (en) 2017-05-30 2018-12-06 The Regents Of The University Of California NANOBODIES AGAINST CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) INHIBITORY FACTOR (Cif)
WO2019000223A1 (en) 2017-06-27 2019-01-03 Nanjing Legend Biotech Co., Ltd. Chimeric antibody immune effctor cell engagers and methods of use thereof
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B cell maturation antigen binding proteins
EP3694529B1 (en) 2017-10-13 2024-06-26 Harpoon Therapeutics, Inc. Trispecific proteins and methods of use
WO2019129221A1 (en) 2017-12-28 2019-07-04 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against tigit
CN111542543B (en) 2017-12-28 2023-12-22 南京传奇生物科技有限公司 Antibodies against PD-L1 and its variants
EP3740507A4 (en) 2018-01-15 2022-08-24 Nanjing Legend Biotech Co., Ltd. SINGLE-DOMAIN ANTIBODIES AND VARIANTS THEREOF AGAINST PD-1
WO2019148089A1 (en) 2018-01-26 2019-08-01 Orionis Biosciences Inc. Xcr1 binding agents and uses thereof
CN112074267B (en) 2018-02-05 2024-06-28 奥里尼斯生物科学公司股份有限公司 Fibroblast binding agent and use thereof
US11958903B2 (en) 2018-03-30 2024-04-16 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies against LAG-3 and uses thereof
BR112020023330A2 (en) 2018-05-14 2021-04-20 Harpoon Therapeutics, Inc. binding portion for conditional activation of immunoglobulin molecules
EP3818085A4 (en) 2018-06-01 2022-03-09 Tayu Huaxia Biotech Medical Group Co., Ltd. COMPOSITIONS AND THEIR USES FOR THE TREATMENT OF DISEASES OR DISORDERS
WO2019227490A1 (en) 2018-06-01 2019-12-05 Tayu Huaxia Biotech Medical Group Co., Ltd. Compositions and methods for imaging
GB2576914A (en) 2018-09-06 2020-03-11 Kymab Ltd Antigen-binding molecules comprising unpaired variable domains produced in mammals
EP3850011A4 (en) 2018-09-10 2022-10-19 Nanjing Legend Biotech Co., Ltd. SINGLE DOMAIN ANTIBODIES AGAINST CD33 AND THEIR CONSTRUCTIONS
US12195544B2 (en) 2018-09-21 2025-01-14 Harpoon Therapeutics, Inc. EGFR binding proteins and methods of use
WO2020069028A1 (en) 2018-09-25 2020-04-02 Harpoon Therapeutics, Inc. Dll3 binding proteins and methods of use
JP7538130B2 (en) 2019-01-23 2024-08-21 タユー ファシャ バイオテック メディカル グループ カンパニー， リミテッド Anti-PD-L1 diabodies and uses thereof
CN114245806A (en) 2019-05-14 2022-03-25 哈普恩治疗公司 Epcam binding proteins and methods of use
CN110818795B (en) 2020-01-10 2020-04-24 上海复宏汉霖生物技术股份有限公司 anti-TIGIT antibodies and methods of use
EP4106806A4 (en) 2020-02-21 2024-07-24 Harpoon Therapeutics, Inc. Flt3 binding proteins and methods of use
KR20220148209A (en) 2020-02-28 2022-11-04 상하이 헨리우스 바이오테크, 인크. Anti-CD137 constructs and uses thereof
AU2021228078A1 (en) 2020-02-28 2022-09-22 Shanghai Henlius Biotech, Inc. Anti-CD137 constructs, multispecific antibody and uses thereof
CN116529260A (en) 2020-06-02 2023-08-01 当康生物技术有限责任公司 anti-CD 93 constructs and uses thereof
JP2023529842A (en) 2020-06-02 2023-07-12 ダイナミキュア バイオテクノロジー エルエルシー Anti-CD93 constructs and uses thereof
CA3187267A1 (en) 2020-06-17 2021-12-23 Janssen Biotech, Inc. Materials and methods for the manufacture of pluripotent stem cells
IL300121A (en) 2020-07-29 2023-03-01 Dynamicure Biotechnology Llc Anti-cd93 constructs and uses thereof
CA3190987A1 (en) 2020-08-10 2022-02-17 Janssen Biotech, Inc. Materials and methods for producing bioengineered virus specific lymphocytes
CN118146382A (en) 2020-09-28 2024-06-07 安济盛生物医药有限公司 Anti-sclerostin constructs and uses thereof
BR112023010168A2 (en) 2020-12-02 2024-02-06 Shanghai Henlius Biotech Inc ANTI-GARP/TGFBETA ANTIBODIES AND METHODS OF USE
WO2022156908A1 (en) 2021-01-25 2022-07-28 Vrije Universiteit Brussel Method for preparing a lyophilized composition
WO2022157373A1 (en) 2021-01-25 2022-07-28 Vrije Universiteit Brussel Compositions and kits for in vivo imaging of cardiac sarcoidosis
WO2022156907A1 (en) 2021-01-25 2022-07-28 Vrije Universiteit Brussel Method and kit for labeling a biomolecule with one or more detectable labels, including a radiolabel
JP7773239B2 (en) 2021-02-19 2025-11-19 シャペロン インク． Bispecific single domain antibodies against PD-L1 and CD47 and uses thereof
CA3209052A1 (en) 2021-02-19 2022-08-25 Rafael Cristian CASELLAS Single domain antibodies that neutralize sars-cov-2
KR102862614B1 (en) 2021-02-19 2025-09-22 (주)샤페론 Single domain antibodies against CD47 and use thereof
AU2022222423B2 (en) 2021-02-19 2025-12-18 Shaperon Inc. Single domain antibody against pd-l1 and use thereof
JP2024509191A (en) 2021-03-05 2024-02-29 ダイナミキュア バイオテクノロジー エルエルシー Anti-VISTA constructs and their uses
CN117616041A (en) 2021-03-25 2024-02-27 当康生物技术有限责任公司 Anti-IGFBP7 constructs and their uses
EP4355785A1 (en) 2021-06-17 2024-04-24 Amberstone Biosciences, Inc. Anti-cd3 constructs and uses thereof
WO2022269473A1 (en) 2021-06-23 2022-12-29 Janssen Biotech, Inc. Materials and methods for hinge regions in functional exogenous receptors
WO2023057508A1 (en) 2021-10-05 2023-04-13 Vrije Universiteit Brussel Fluorescently labeled immunoglobulin single variable domai ns
EP4448579A1 (en) 2021-12-17 2024-10-23 Shanghai Henlius Biotech, Inc. Anti-ox40 antibodies and methods of use
CA3240585A1 (en) 2021-12-17 2023-06-22 Wenfeng Xu Anti-ox40 antibodies, multispecific antibodies and methods of use
KR20240163119A (en) 2022-03-25 2024-11-18 상하이 헨리우스 바이오테크, 인크. Anti-MSLN antibodies and methods of use
CA3262611A1 (en) 2022-07-22 2024-01-25 Janssen Biotech, Inc. Enhanced transfer of genetic instructions to effector immune cells
CN120077071A (en) 2022-09-07 2025-05-30 当康生物技术有限责任公司 Anti-VISTA constructs and uses thereof
EP4349374A1 (en) 2022-10-05 2024-04-10 Vrije Universiteit Brussel Anti-urokinase plasminogen activator receptor immunoglobulin single variable domains
EP4605077A1 (en) 2022-10-18 2025-08-27 Confo Therapeutics N.V. Amino acid sequences directed against the melanocortin 4 receptor and polypeptides comprising the same for the treatment of mc4r-related diseases and disorders
WO2025034806A1 (en) 2023-08-08 2025-02-13 Wisconsin Alumni Research Foundation Single-domain antibodies and variants thereof against fibroblast activation protein
EP4512243A1 (en) 2023-08-21 2025-02-26 Kymab Limited Binding molecules
WO2025045251A2 (en) 2023-09-03 2025-03-06 Kira Pharmaceuticals (Us) Llc Multispecific constructs comprising anti-factor d moiety
WO2025088085A1 (en) 2023-10-26 2025-05-01 Abscint Nv Image guided biopsy of her2 positive lesions
WO2025178959A1 (en) 2024-02-20 2025-08-28 University Of Georgia Research Foundation, Inc. Single-domain antibodies and variants thereof against tab1

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0110029D0 (en) * 2001-04-24 2001-06-13 Grosveld Frank Transgenic animal
GB0115256D0 (en) * 2001-06-21 2001-08-15 Babraham Inst Mouse light chain locus

Also Published As

Publication number Publication date
AU2003295086A8 (en) 2004-06-23
WO2004049794A2 (en) 2004-06-17
WO2004049794A3 (en) 2004-12-02
GB0228210D0 (en) 2003-01-08

Similar Documents

Publication Publication Date Title
AU2003295086A1 (en) Single chain antibodies produced in a transgenic mouse
AU2003217912A1 (en) Antibody optimization
GB0504974D0 (en) Subsurface illumination, a hybrid wave equation-ray-tracing method
AU2003229638A1 (en) Plane chain strand comprising a chain lock link
AU2003295148A1 (en) A combustion device
AU2003208404A1 (en) A couplig
AU2003902483A0 (en) A bioelastomer ii
AU2002953172A0 (en) A Cladding Element
GB2404355B (en) A sawmill
AU2003248999A1 (en) A case
AU2003246545A1 (en) Problem solving by a cad program
AU2003211128A1 (en) Transgenic production in saliva
AU2002100695A4 (en) A mat
AU2003278554A1 (en) A shellfish dredge
AU2003100320A4 (en) A method for carrying out a design project
AU2002953337A0 (en) A conveyor
AU2002953331A0 (en) A conveyor
AU2003264173A1 (en) A zip
AUPR998402A0 (en) A reconfigurable interface
AU2003906367A0 (en) A Conveyor
AU2002101033A4 (en) A Guitar Hook
AU2002952437A0 (en) A saddle
AUPS170602A0 (en) A luminaire
AU2003906035A0 (en) A transporter
AU2003902635A0 (en) A transporter

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase